The GLP is committed to full transparency. Download and review our Annual Report.

Gene patent ruling leaves unanswered questions

A seemingly decisive Supreme Court ruling against gene patents in June left a lot of issues unsettled, and the industry can expect much more litigation to come, experts say.

The decision invalidated patents claimed by Myriad Genetics against rival Ambry Genetics on the use of naturally occurring DNA sequences in tests for the risk of breast cancer. Yet on July 9, Myriad filed another lawsuit against Ambry and Gene by Gene, citing other patent violations

The Myriad case marks the beginning of a cultural shift in how biotech patents are viewed, to take into account public needs, said University of Michigan researcher Shobita Parthasarathy. But other decisions, and a change of attitude from the U.S. Patent and Trademark Office, will be needed to confirm that shift.

Read the full, original story here: Gene patent ruling leaves unanswered questions

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend